Literature DB >> 18497467

Renal thrombotic microangiopathies induced by severe hypertension.

Bo Zhang1, Changying Xing, Xiangbao Yu, Bin Sun, Xiufen Zhao, Jun Qian.   

Abstract

Renal thrombotic microangiopathy (TMA) is an uncommon vascular complication of severe hypertension. Until now, its clinical-pathological characteristics and renal survival have been unclear. Twenty-one patients with biopsy-proven renal TMA and with severe or malignant hypertension were retrospectively studied. All the patients exhibited severe hypertension, with systolic blood pressure at 200-280 mmHg and diastolic pressure at 110-180 mmHg. No patients had hemorrhagic manifestations. Elevated lactate dehydrogenase and thrombocytopenia were found in 6 and 5 patients, respectively. Significant proteinuria (>3 g/day) was present in 2 patients and microscopic hematuria in 18 patients. All patients presented with renal insufficiency (creatinine 3.1+/-2.1 mg/dL). The level of von Willebrand factor:antigen (vWF:Ag) in patients was not significantly higher than that in the healthy subjects, while the ADAMTS13 (a disintegrin and metalloprotease, with thrombospondin-1-like domains) activity was not significantly lower than that in the healthy subjects. Renal histology showed a TMA involving preglomerular arterioles and/or interlobular arteries characterized by fibrin deposits and vascular wall sclerosis. Fibrin glomerular microthrombi were not observed in these patients. Four patients required hemodialysis upon admission for severe acute renal failure. On follow-up, 3 patients had recovered normal renal function and 14 had mild renal insufficiency (creatinine 1.8+/-0.3 mg/dL), while 4 patients still required persistent hemodialysis. In conclusion, compared with patients having hemolytic uremic syndrome/thrombocytopenic purpura, our patients showed a low incidence of thrombocytopenia and better renal outcome.

Entities:  

Mesh:

Year:  2008        PMID: 18497467     DOI: 10.1291/hypres.31.479

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  14 in total

1.  C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension.

Authors:  Sjoerd A M E G Timmermans; Myrurgia A Abdul-Hamid; Judith Potjewijd; Ruud O M F I H Theunissen; Jan G M C Damoiseaux; Chris P Reutelingsperger; Pieter van Paassen
Journal:  J Am Soc Nephrol       Date:  2018-06-01       Impact factor: 10.121

2.  Renal denervation for resistant hypertension: the wrong target?

Authors:  Shi-Sheng Zhou; Yiming Zhou
Journal:  Nat Rev Cardiol       Date:  2016-06-03       Impact factor: 32.419

3.  A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy.

Authors:  Khalil El Karoui; Gary S Hill; Alexandre Karras; Christian Jacquot; Luc Moulonguet; Olivier Kourilsky; Véronique Frémeaux-Bacchi; Michel Delahousse; Jean-Paul Duong Van Huyen; Alexandre Loupy; Patrick Bruneval; Dominique Nochy
Journal:  J Am Soc Nephrol       Date:  2011-11-03       Impact factor: 10.121

4.  Malignant hypertension complicated by acute renal failure.

Authors:  Xiao Li; Wen Zhang; Hong Ren; Xiaoxia Pan; Nan Chen
Journal:  BMJ Case Rep       Date:  2009-06-15

5.  Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura.

Authors:  Nabin Khanal; Sumit Dahal; Smrity Upadhyay; Vijaya Raj Bhatt; Philip J Bierman
Journal:  Ther Adv Hematol       Date:  2015-06

Review 6.  Hypertensive crisis in children.

Authors:  Jayanthi Chandar; Gastón Zilleruelo
Journal:  Pediatr Nephrol       Date:  2011-07-20       Impact factor: 3.714

7.  Hypertensive crisis in children and adolescents.

Authors:  Tomáš Seeman; Gilad Hamdani; Mark Mitsnefes
Journal:  Pediatr Nephrol       Date:  2018-10-01       Impact factor: 3.714

8.  Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis.

Authors:  Julien Mahe; Aurélie Meurette; Anne Moreau; Caroline Vercel; Pascale Jolliet
Journal:  Drug Des Devel Ther       Date:  2013-08-07       Impact factor: 4.162

Review 9.  Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.

Authors:  Arif Asif; Ali Nayer; Christian S Haas
Journal:  J Nephrol       Date:  2016-11-15       Impact factor: 3.902

10.  Genetic testing of complement and coagulation pathways in patients with severe hypertension and renal microangiopathy.

Authors:  Christopher P Larsen; Jon D Wilson; Alejandro Best-Rocha; Marjorie L Beggs; Randolph A Hennigar
Journal:  Mod Pathol       Date:  2017-11-17       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.